Intercept Pharma (ICPT) – Hot Guidance
-
Intercept Pharma (ICPT) Misses Q3 EPS by 8c, Revenues Beat; Offers FY20 Ocaliva Net Sales Mid-Point Guidance Above Consensus
-
Intercept Pharma (ICPT) Misses Q3 EPS by 16c, Revenues Miss; Raises FY19 Ocaliva Net Sales Outlook
-
-
Back to ICPT Stock Lookup